

2nd June, 2025

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma Limited's facility at Aurora, Canada from 26th May 2025 to 30th May, 2025.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

The Company remains committed to maintain the highest standards of compliance.

This is for your information and records.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary